DCC4757 |
Skf-99101h |
Selective, brain penetrant 5-HT(1B/D) receptor agonist |
|
DCC4758 |
Ski-349 |
Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization |
|
DCC4759 |
Ski-417616 |
Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV) |
|
DCC4760 |
S-kkwk |
Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin |
|
DCC4761 |
sklb023 |
Novel inhibitor of NF |
|
DCC4762 |
Sklb028 |
Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin |
|
DCC4763 |
Sklb050 |
Biological Active Reagents |
|
DCC4764 |
Sklb-163 |
Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK |
|
DCC4765 |
Sklb-329 |
Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase |
|
DCC4766 |
Sklb-677 |
Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML |
|
DCC4767 |
Sklb70326 |
Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells |
|
DCC4768 |
Skog102 |
Novel inhibitor of OLIG2 in glioblastoma |
|
DCC4769 |
skp Inhibitor C16 |
Specific Inhibitor of Skp2-Mediated p27 Degradation |
|
DCC4770 |
skp Inhibitor C20 |
Specific Inhibitor of Skp2-Mediated p27 Degradation |
|
DCC4771 |
Skp2 Inhibitor C2 |
First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation |
|
DCC4772 |
Sl-1-73 |
Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma |
|
DCC4773 |
Sl-3-19 |
Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma |
|
DCC4774 |
Sl-651498 |
Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits. |
|
DCC4775 |
Sl910102 |
Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19 |
|
DCC4776 |
Slec-8 |
Potential synthetic lethal lead, targeting E-cadherin-deficient cells |
|
DCC4777 |
Slk/stk10-in-31 |
Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10) |
|
DCC4778 |
Sll-039 |
Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283) |
|
DCC4779 |
Slm6071469 |
Novel potent SphK2-selective inhibitor (Ki = 89 nM, 73-fold SphK2-selective) with validated in vivo activity |
|
DCC4780 |
Slp120701 |
Novel SphK2-selective inhibitor with improved half-life to 8 h in mice |
|
DCC4781 |
Slp7111228 |
Novel selective SphK1 inhibitor |
|
DCC4782 |
Slr080811 |
Novel SphK2-selective inhibitor |
|
DCC4783 |
Slupp-225 |
Novel efflux pump inhibitor (EPI) |
|
DCC4784 |
Slupp-417 |
Novel efflux pump inhibitor (EPI) |
|
DCC4785 |
Sm-130686 |
Potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue |
|
DCC4786 |
Sm-131 |
Novel Potent, Cell-Permeable, Conformationally Constrained Second Mitochondria Derived Activator of Caspase (Smac) Mimetic |
|